1. Home
  2. Directory
  3. South Carolina
  4. Charleston
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1457930554

JESSICA DIAL DNP, FNP-C
Prescription History 1457930554
Nurse Practitioner - Family in Charleston, SC


Quality Rating: 73.84 out of 100 score

NPI Status: Active since April 06, 2021

Contact Information

171 ASHLEY AVE
CHARLESTON, SC
ZIP 29425
Phone: (843) 792-1414

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for JESSICA DIAL DNP, FNP-C, an active Family specialist practicing in Charleston, SC. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 99 documented patient claims. Among these therapy options, the most frequently utilized medication is Novolog Flexpen, which accounts for 31 claims alone.

Medication Index

Humalog Kwikpen U-100

Generic Formulation: Insulin LisproSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 18
30-Day Fills 23.6
Days Supply 700
SC State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills47.2
Peer Average Days Supply1,356
Conservative Utilization

This provider writes prescriptions for this formulation 30.8% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,333.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$629.66

State Avg Cost Per Claim

$936.89

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.

Therapeutic Applications

Insulin lispro is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin lispro is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin lispro starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product. Insulin lispro may also be used with other oral diabetes medications (such as sulfonylureas like glyburide or glipizide).

Lantus Solostar

Generic Formulation: Insulin Glargine,hum.Rec.AnlogSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 54.0
Days Supply 1,620
SC State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills62.4
Peer Average Days Supply1,804
Conservative Utilization

This provider writes prescriptions for this formulation 42.4% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,363.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$492.81

State Avg Cost Per Claim

$696.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A recombinant LONG ACTING INSULIN and HYPOGLYCEMIC AGENT that is used to manage BLOOD GLUCOSE in patients with DIABETES MELLITUS.

Therapeutic Applications

Insulin glargine is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin glargine is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. It acts longer than regular insulin, providing a low, steady level of insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. Insulin glargine may be used with a shorter-acting insulin product. It may also be used alone or with other diabetes drugs. This monograph is about the following insulin glargine products: insulin glargine, insulin glargine-yfgn.

Novolog Flexpen

Generic Formulation: Insulin AspartSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 31
30-Day Fills 45.3
Days Supply 1,357
SC State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills48.9
Peer Average Days Supply1,341
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,385.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$625.35

State Avg Cost Per Claim

$897.35

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Insulin that has been modified to contain an ASPARTIC ACID instead of a PROLINE at position 38 of the B-chain.

Therapeutic Applications

Insulin aspart is used with a proper diet and exercise program to control high blood sugar in people with diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Proper control of diabetes may also lessen your risk of a heart attack or stroke. Insulin aspart is a man-made product that is similar to human insulin. It replaces the insulin that your body would normally make. Insulin aspart starts working faster and lasts for a shorter time than regular insulin. It works by helping blood sugar (glucose) get into cells so your body can use it for energy. This medication is usually used with a medium- or long-acting insulin product.

Techlite Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 21.7
Days Supply 615
SC State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills36.3
Peer Average Days Supply1,038
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $541.32 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.83

State Avg Cost Per Claim

$27.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Trueplus Pen Needle

Generic Formulation: Pen Needle, DiabeticSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 15
30-Day Fills 21.7
Days Supply 617
SC State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills39.2
Peer Average Days Supply1,148
Conservative Utilization

This provider writes prescriptions for this formulation 34.8% less frequently than the standard regional baseline metric for practitioners inside SC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $379.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.32

State Avg Cost Per Claim

$29.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like JESSICA DIAL DNP, FNP-C provides transparency into local medical care patterns within Charleston, SC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Family** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.